NCT06590558 2025-07-03Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerNational Cancer Institute (NCI)Phase 1 Withdrawn